Streetbeat News

Acquisitions Mergers

LLY

NVO

Novo Nordisk has agreed to pay up to $2 billion for UBT251, an experimental obesity drug from United Laboratories International. The drug uniquely targets three gut hormones (GLP-1, GIP, and glucagon), potentially offering more potent weight loss effects. This move positions Novo Nordisk to compete with Eli Lilly's obesity drug market, though Eli Lilly's retatrutide might reach the market earlier.

Portfolio Pulse from

March 25, 2025 | 5:15 pm

HBAN

Capstone Partners' Annual Consumer M&A Report reveals a positive outlook for 2025, with consumer M&A volume rebounding in 2024. Approximately 70% of transactions were strategic corporate acquisitions, and middle market CEOs show increased optimism. Key sectors like Tactical, Home Goods, E-Commerce, and Sports Technology are outperforming, and a potential rotation from Consumer Staples to Consumer Discretionary is anticipated.

Portfolio Pulse from

March 25, 2025 | 5:15 pm

ABVE

Above Food Ingredients Inc. (ABVE) has successfully signed a $9 million convertible notes private placement with institutional investors. $7 million will fund immediately, with the remaining $2 million contingent on a potential reverse merger with Palm Global Technologies Ltd. The funds will be used to accelerate growth for their Montana-based subsidiary Stricks Ag LLC and support strategic initiatives in AI-driven genomics and agri-tech.

Portfolio Pulse from

March 25, 2025 | 4:15 pm

LLY

ONVO

Organovo Holdings has completed the sale of its FXR program, including lead asset FXR314, to Eli Lilly and Company. The transaction includes an upfront payment and potential future milestone payments, with Lilly acquiring worldwide commercial and intellectual property rights and taking over future clinical development.

Portfolio Pulse from

March 25, 2025 | 3:45 pm

FNA

Kaskela Law LLC is investigating the fairness of Zimmer Biomet's proposed acquisition of Paragon 28, Inc. at $13.00 per share plus a potential $1.00 contingent value right. The law firm questions whether shareholders are receiving sufficient compensation, noting that stock analysts previously had price targets at or above $15.00 per share.

Portfolio Pulse from

March 25, 2025 | 3:45 pm

GS

Fleetio, a fleet optimization software platform, has acquired Auto Integrate and raised over $450 million in Series D funding, valuing the combined business at $1.5 billion. The strategic merger aims to create a comprehensive, customer-centric fleet maintenance solution serving over 8 million vehicles and processing 13 million repair orders annually across North America.

Portfolio Pulse from

March 25, 2025 | 3:15 pm

CTAS

UNF

UniFirst Corp (UNF) stock dropped 13.5% after Cintas terminated a $5.3 billion buyout offer that would have valued the company at $275 per share. UBS subsequently reduced its price target, and the stock is now struggling near its year-to-date breakeven point ahead of its upcoming earnings report.

Portfolio Pulse from

March 25, 2025 | 3:15 pm

GS

Fleetio, a fleet optimization software platform, has acquired Auto Integrate and raised over $450 million in Series D funding, valuing the combined business at $1.5 billion. The strategic merger aims to create a comprehensive, customer-centric fleet maintenance solution serving over 8 million vehicles and processing 13 million repair orders annually across North America.

Portfolio Pulse from

March 25, 2025 | 3:15 pm

KR

Kroger has filed legal counterclaims against Albertsons in the Delaware Court of Chancery, alleging that Albertsons undermined the merger process through secret communications and strategic misconduct. Kroger claims Albertsons is not entitled to the $600 million termination fee and is seeking damages for the investment made in pursuing regulatory approval.

Portfolio Pulse from

March 25, 2025 | 2:45 pm

KR

Kroger has filed legal counterclaims against Albertsons in the Delaware Court of Chancery, alleging that Albertsons undermined the merger process through secret communications and strategic misconduct. Kroger claims Albertsons is not entitled to the $600 million termination fee and is seeking damages for the investment made in pursuing regulatory approval.

Portfolio Pulse from

March 25, 2025 | 2:45 pm